Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Income towards Parent Company: 2010-2021

Historic Income towards Parent Company for Neurocrine Biosciences (NBIX) over the last 12 years, with Sep 2021 value amounting to $22.5 million.

  • Neurocrine Biosciences' Income towards Parent Company rose 139.06% to $22.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $39.3 million, marking a year-over-year decrease of 57.93%. This contributed to the annual value of $37.0 million for FY2019, which is 75.32% up from last year.
  • Neurocrine Biosciences' Income towards Parent Company amounted to $22.5 million in Q3 2021, which was down 46.81% from $42.3 million recorded in Q2 2021.
  • Over the past 5 years, Neurocrine Biosciences' Income towards Parent Company peaked at $79.6 million during Q2 2020, and registered a low of -$102.1 million during Q1 2019.
  • Over the past 3 years, Neurocrine Biosciences' median Income towards Parent Company value was $35.7 million (recorded in 2019), while the average stood at $19.3 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Income towards Parent Company tumbled by 293.66% in 2017, and later spiked by 967.58% in 2019.
  • Neurocrine Biosciences' Income towards Parent Company (Quarterly) stood at $6.9 million in 2017, then soared by 172.82% to $18.8 million in 2018, then surged by 80.84% to $34.0 million in 2019, then slumped by 207.06% to -$57.6 million in 2020, then soared by 139.06% to $22.5 million in 2021.
  • Its Income towards Parent Company was $22.5 million in Q3 2021, compared to $42.3 million in Q2 2021 and $32.1 million in Q1 2021.